Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1B3VP
|
|||
| Drug Name |
Modakafusp alfa
|
|||
| Synonyms |
TAK-573
Click to Show/Hide
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1/2 | [2] | ||
| Company |
TAKEDA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04157517) An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05590377) A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.